Structure via PubChem · Public domain (PubChem)
2C-T-17
Sign in to saveAlso known as 4-(sec-butylthio)-2,5-dimethoxyphenethylamine, NIMITZ, 4-sec-butylthio-2,5-dimethoxyphenethylamine, 2,5-dimethoxy-4-sec-butylthiophenethylamine, 2-{4-[(butan-2-yl)sulfanyl]-2,5-dimethoxyphenyl}ethan-1-amine, 2-[4-(butan-2-ylsulfanyl)-2,5-dimethoxyphenyl]ethan-1-amine, 2-(4-butan-2-ylsulfanyl-2,5-dimethoxyphenyl)ethanamine
2C-T-17, also known as '4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz', is a psychedelic drug of the phenethylamine and 2C families. It is taken orally.
Chemical data
- Formula
- C14H23NO2S
- Molecular weight
- 269.4 g/mol
- IUPAC name
- 2-(4-butan-2-ylsulfanyl-2,5-dimethoxyphenyl)ethanamine
- SMILES
- CCC(C)SC1=C(C=C(C(=C1)OC)CCN)OC
- InChIKey
- KSZHVRPGICAZOA-UHFFFAOYSA-N
- XLogP
- 3.1
- Polar surface area
- 69.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
Show 6 more facts
- canonical SMILES
- CCC(C)SC1=C(C=C(C(=C1)OC)CCN)OC
- chemical formula
- C₁₄H₂₃NO₂S
- Commons category
- 2C-T-17
- discoverer or inventor
- Alexander Shulgin
- subject has role
- psychedelic drug
- described by source
- Phenethylamines I Have Known And Loved
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
16 sectionsContents
- Use and effects
- Toxicity
- Interactions
- Pharmacology
- Pharmacodynamics
- Chemistry
- Synthesis
- History
- Society and culture
- Legal status
- Canada
- United Kingdom
- United States
- See also
- References
- External links
2C-T-17, also known as '4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz', is a psychedelic drug of the phenethylamine and 2C families. It is taken orally.
2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991. Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Excerpted from Wikipedia’s “2C-T-17” article, available under the CC BY-SA 4.0 licence.